Sandoz, the generic pharmaceuticals division of Novartis, is a worldwide leader in generics. With a history of more than 120 years, Sandoz is a trusted leader with a reputation for exceptional quality. Our strategic and customer-focused approach to developing, producing and marketing high-quality affordable medicines following the loss of patent protection, has successfully made us one of the two largest and most respected generics companies worldwide. Our medicines are already available to 90 percent of people across the world and we are committed to further increasing global access to affordable healthcare.Our comprehensive global development and production network and worldwide commercial presence are complemented by a wide range of standard and differentiated products covering all stages of the development and production processes, from basic molecules to finished medicines. This combination of specialist expertise and extensive global presence, underpinned by an unwavering commitment to quality, gives us a competitive advantage that clearly sets us apart from the competition. By offering a broad portfolio of high-quality affordable medicines, Sandoz also contributes to the stability of healthcare systems worldwide, providing significant savings that can be used for the funding of costlier novel therapies, thus encouraging continued pharmaceutical innovation. In this way, Sandoz represents a key pillar of the overall Novartis strategy of offering an all-inclusive range of medicines to patients, physicians and healthcare providers along the entire healthcare spectrum.